Recent News

• 11.02.2026 - IDEXX Laboratories Announces Third Quarter Results
• 10.01.2026 - IDEXX Laboratories to Release 2026 Third Quarter Financial Results
• 09.17.2026 - IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
• 09.16.2026 - IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
• 08.31.2026 - IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
• 08.11.2026 - IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
• 08.04.2026 - IDEXX Laboratories Announces Second Quarter Results
• 07.28.2026 - IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
• 07.01.2026 - IDEXX Laboratories to Release 2026 Second Quarter Financial Results
• 05.26.2026 - IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection

Recent Filings

• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.02.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.02.2026 - 8-K Current report
• 11.02.2026 - EX-99.1 EX-99.1
• 10.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2026 - 144 Report of proposed sale of securities
• 08.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report